Use of the levonorgestrel-releasing intrauterine system: An Austrian perspective

Current Opinion in Obstetrics and Gynecology

Volumn 21, Issue SUPPL. 1, 2009, Pages

  Concin, Hans ^a   Bösch, Hubert ^a   Hintermüller, Peter ^b   Hohlweg, Thomas ^c   Mursch Edlmayr, Gerhard ^d   Pinnisch, Bettina ^e   Schmidl Amann, Sigrid ^b   Schulz Greinwald, Gunda ^f   Unterlerchner, Dagmar ^g   Wagner, Teresa ^a   Mattle, Verena ^h   Wildt, Ludwig ^h   Fiala, Christian ^e  

^a Landeskrankenhaus Bregenz ^*  (Austria)

^b Private Clinic   (Austria)

^c Private Clinic   (Austria)

^d Private Clinic   (Austria)

^e Private Clinic Doebling   (Austria)

^f Private Clinic   (Austria)

^g Private Clinic   (Austria)

^h University Clinic of Gynaecology   (Austria)

Author keywords

Contraception; Intrauterine device; Levonorgestrel releasing intrauterine system; Longacting reversible contraceptive methods

Indexed keywords

CYPROTERONE ACETATE; DICLOFENAC; FLUTAMIDE; GEMEPROST; GESTAGEN; ISOTRETINOIN; LEVONORGESTREL; MIFEPRISTONE; MISOPROSTOL; PROSTAGLANDIN E2; SULPROSTONE; TAMOXIFEN; TETRACYCLINE DERIVATIVE;

ACNE; ALOPECIA; AUSTRIA; BREAST CANCER; CANCER RISK; CLINICAL TRIAL; DEPRESSION; DEVICE REMOVAL; DIARRHEA; DRUG ABSORPTION; DRUG COST; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG RELEASE; DRUG WITHDRAWAL; ECTOPIC PREGNANCY; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; LAMINARIA; LIBIDO; LOW DRUG DOSE; NULLIPARA; OVARY FOLLICLE ATRESIA; PATIENT SATISFACTION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SPOTTING; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CONIZATION; UTERINE CERVIX DILATATION; VAGINA BLEEDING; WEIGHT CHANGE; WEIGHT GAIN;

ADMINISTRATION, INTRAVAGINAL; AUSTRIA; CONTRACEPTION; CONTRACEPTIVE AGENTS, FEMALE; FEMALE; HUMANS; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL; PATIENT SATISFACTION; RISK FACTORS; TIME FACTORS;

EID: 70449092009     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.gco.0000361658.98177.59     Document Type: Review

References (48)

1. Electronic Medicines Compendium. Mirena. Summary of product characteristics. 27 June 2008. Available from: http://emc.medicines.org.uk/emc/ assets/c/html/displayDocPrinterFriendly.asp?documentid=1829. Accessed: 19 November 2008.
2. Vercellini P, Vigano P, Somigliana E. The role of the levonorgestrel-releasing intrauterine device in the management of symptomatic endometriosis. Curr Opin Obstet Gynecol 2005; 17:359-365.
3. Bragheto AM, Caserta N, Bahamondes L, et al. Effectiveness of the levonorgestrel- releasing intrauterine system in the treatment of adenomyosis diagnosed and monitored by magnetic resonance imaging. Contraception 2007; 76:195-199.
4. Bayer Schering Pharma (data on file). Mirena, Berlin; 2007.
5. Fiala C, Gemzell-Danielsson K, Tang OS, et al. Cervical priming with misoprostol prior to transcervical procedures. Int J Gynaecol Obstet 2007; 99 (Suppl. 2):S168-S171.
6. World Health Organization. Safe abortion: technical and policy guidance for health systems. Available from: http://www.who.int/reproductive-health/ publications/ safe-abortion/safe-abortion.pdf. Accessed: 19 November 2008.
7. Fiala C, Gemzel-Danielsson K. Review of medical abortion using mifepristone incombination with a prostaglandin analogue. Contraception 2006; 74:66-86.
8. Saav I, Aronsson A, Marions L, et al. Cervical priming with sublingual misoprostol prior to insertion of an intrauterine device in nulliparous women: a randomized controlled trial. Hum Reprod 2007; 22:2647-2652.
9. Celentano C, Prefumo F, Di Andrea O, et al. Oral misoprostol vs. vaginal gemeprost prior to surgical termination of pregnancy in nulliparae. Acta Obstet Gynecol Scand 2004; 83:764-768.
10. Preutthipan S, Herabutya Y. A randomized comparison of vaginal misoprostol and dinoprostone for cervical priming in nulliparous women before operative hysteroscopy. Fertil Steril 2006; 86:990-994.
11. Singh K, Fong YF, Prasad RN, et al. Randomized trial to determine optimal dose of vaginal misoprostol for preabortion cervical priming. Obstet Gynecol 1998; 92:795-798.
12. Aronsson A, Bygdeman M, Gemzell-Danielsson K. Effects of misoprostol on uterine contractility following different routes of administration. Hum Reprod 2004; 19:81-84.
13. Blanchard K, Clark S, Winikoff B, et al. Misoprostol for women's health: a review. Obstet Gynecol 2002; 99:316-332.
14. Fliers E, Duren DR, Van Zwieten PA. A prostaglandin analogue as a probable cause of myocardial infarction in a young woman. BMJ 1991; 302:416.
15. Ashok PW, Flett GM, Templeton A. Mifepristone versus vaginally administered misoprostol for cervical priming before first-trimester termination of pregnancy: a randomized, controlled study. Am J Obstet Gynecol 2000; 183:998-1002.
16. Sperling AL. A randomized controlled trial of laminaria, oral misoprostol, and vaginal misoprostol before abortion. Obstet Gynecol 1999; 93:766-770.
17. MacIsaac L, Grossman D, Balistreri E, et al. A randomized controlled trial of laminaria, oral misoprostol, and vaginal misoprostol before abortion. Obstet Gynecol 1999; 93:766-770. (Pubitemid 29190679)
18. Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copperreleasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception 1994; 49:56-72.
19. Fraser IS. The promise and reality of the intrauterine route for hormone delivery for prevention and therapy of gynecological disease. Contraception 2007; 75 (6 Suppl):S112-S117.
20. HaukkamaaM, Holma P. Five-year clinical performance of the new formulation of the levonorgestrel intrauterine system and serum levonorgestrel concentration with the new formulation compared to that with the original one. Leiras Clinical Study Report 1 1996; No 02-89532-07.
21. Suhonen SP, Holmstrom T, Allonen HO, et al. Intrauterine and subdermal progestin administration in postmenopausal hormone replacement therapy. Fertil Steril 1995; 63:336-342.
22. Backman T, Huhtala S, Blom T, et al. Length of use and symptoms associated with premature removal of the levonorgestrel intrauterine system: a nationwide study of 17,360 users. Br J Obstet Gynecol 2000; 107:335-339.
23. Elovainio M, Teperi J, Aalto AM, et al. Depressive symptoms as predictors of discontinuation of treatment of menorrhagia by levonorgestrel-releasing intrauterine system. Int J Behav Med 2007; 14:70-75.
24. Paterson H, Clifton J, Miller D, et al. Hair loss with use of the levonorgestrel intrauterine device. Contraception 2007; 76:306-309.
25. Cox M, Tripp J, Blacksell S. Clinical performance of the levonorgestrel intrauterine system in routine use by the UK Family Planning and Reproductive Health Research Network: 5-year report. J Fam Plann Reprod Health Care 2002; 28:73-77. (Pubitemid 34595935)
26. Daud S, Ewies AA. Levonorgestrel-releasing intrauterine system: why do some women dislike it? Gynecol Endocrinol 2008; 24:686-690.
27. Robinson G, Bounds W, Kubba A, et al. Functional ovarian cysts associated with the levonorgestrel-releasing intrauterine device. Br J Fam Plann 1989; 14:131-132.
28. Bahamondes L, Hidalgo M, Petta CA, et al. Enlarged ovarian follicles in users of a levonorgestrel-releasing intrauterine system and contraceptive implant. J Reprod Med 2003; 48:637-640.
29. Hopkins MR, Agudelo-Suarez P, El-Nashar SA, et al. Term pregnancy with intraperitoneal levonorgestrel intrauterine system: a case report and review of the literature. Contraception 2009; 79:323-327.
30. Sivin I. Extrauterine pregnancies and intrauterine devices reassessed. In: Bardin CW, Mishell DR, editors. Fourth International Conference on IUDs. London: Butterworth-Heinemann; 1994. pp. 195-209.
31. Prager S, Darney P. Can the levonorgestrel-releasing intrauterine system (Mirena) be used in nulliparous women? Gynaecology Forum 2006; 11: No 2.
32. Prager SDP. The levonorgestrel intrauterine system in nulliparous women. Contraception 2007; 75 (6 Suppl.):S12-S15.
33. Rosenberg MJ BM, Waugh MS, Grimes DA, Hillard PJ. Compliance and oral contraceptives: a review. Contraception 1995; 52:137-141.
34. Tafelski T, Boehm KE. Contraception in the adolescent patient. Prim Care 1995; 22:145-159.
35. Serfaty D. Oral contraceptive compliance during adolescence. Ann NY Acad Sci 1997; 816:422-431.
36. Suhonen S, Haukkamaa M, Jakobsson T, et al. Clinical performance of a levonorgestrel-releasing intrauterine system and oral contraceptives in young nulliparous women: a comparative study. Contraception 2004; 69:407-412.
37. Viberga I, Odlind V, Lazdane G. Characteristics of women at low risk of STI presenting with pelvic inflammatory disease. Eur J Contracept Reprod Health Care 2006; 11:60-68.
38. Hubacher D, Lara-Ricalde R, Taylor DJ, et al. Use of copper intrauterine devices and the risk of tubal infertility among nulligravid women. N Engl J Med 2001; 345:561-567.
39. Backman T, Rauramo I, Jaakkola K, et al. Use of the levonorgestrel- releasing intrauterine system and breast cancer.Obstet Gynecol 2005; 106:813-817.
40. Dinger JC, Voigt K, Westhoff C. Breast cancer risk associated with use of levonorgestrel-releasing and copper intrauterine devices. Poster presented at the American College of Obstericians and Gynecologists Annual Meeting. Chicago, IL, 5 May 2009 [Poster 2].
41. Sivin I. Risks and benefits, advantages and disadvantages of levonorgestrelreleasing contraceptive implants. Drug Saf 2003; 26:303-335.
42. Curtis KM. Safety of implantable contraceptives for women: data from observational studies. Contraception 2002; 65:85-96.
43. Trinh XB, Tjalma WA, Makar AP, et al. Use of the levonorgestrel-releasing intrauterine system in breast cancer patients. Fertil Steril 2008; 90:17-22.
44. Schoonen WG, Joosten JW, Kloosterboer HJ. Effects of two classes of progestagens, pregnane and 19-nortestosterone derivatives, on cell growth of human breast tumor cells: II. T47D cell lines. J Steroid Biochem Mol Biol 1995; 55:439-444.
45. Schoonen WG, Joosten JW, Kloosterboer HJ. Effects of two classes of progestagens, pregnane and 19-nortestosterone derivatives, on cell growth of human breast tumor cells: I. MCF-7 cell lines. J Steroid Biochem Mol Biol 1995; 55:423-437.
46. Chan SS, Tam WH, YeoW, et al. A randomised controlled trial of prophylactic levonorgestrel intrauterine system in tamoxifen-treated women. Br J Obstet Gynecol 2007; 114:1510-1515.
47. Weissauer A. 66 RZ 15. In: Laufs A, Uhlenbruck W, eds. Handbuch des Arztrechts. 3. Aufl. Munchen, 2002.
48. Pok J, Wyss P, Honegger C. Leitfaden zum ärztlichen Aufklärungsgespräch. Schweizerische Ärztezeitung 2007; 88:266-267.